Novel infectivity-enhanced oncolytic adenovirus With a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer

Kristopher Kimball, Angel A. Rivera, Kurt R. Zinn, Mert Icyuz, Vaibhav Saini, Jing Li, Zeng B. Zhu, Gene P. Siegal, Joanne T. Douglas, David T. Curiel, Ronald D. Alvarez, Anton V. Borovjagin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We sought to develop a cancer-targeted, infectivity-enhanced oncolytic adenovirus that embodies a capsid-labeling fusion for noninvasive dual-modality imaging of ovarian cancer virotherapy. A functional fusion protein composed of fl uorescent and nuclear imaging tags was genetically incorporated into the capsid of an infectivity-enhanced conditionally replicative adenovirus. Incorporation of herpes simplex virus thymidine kinase (HSV-tk) and monomeric red fl uorescent protein 1 (mRFP1) into the viral capsid and its genomic stability were verifi ed by molecular analyses. Replication and oncolysis were evaluated in ovarian cancer cells. Fusion functionality was confi rmed by in vitro gamma camera and fl uorescent microscopy imaging. Comparison of tk-mRFP virus to singlemodality controls revealed similar replication effi ciency and oncolytic potency. Molecular fusion did not abolish enzymatic activity of HSV-tk as the virus effectively phosphorylated thymidine both ex vivo and in vitro. In vitro fl uorescence imaging demonstrated a strong correlation between the intensity of fl uorescent signal and cytopathic effect in infected ovarian cancer cells, suggesting that fl uorescence can be used to monitor viral replication. We have in vitro validated a new infectivity-enhanced oncolytic adenovirus with a dual-imaging modality-labeled capsid, optimized for ovarian cancer virotherapy. The new agent could provide incremental gains toward climbing the barriers for achieving conditionally replicated adenovirus effi cacy in human trials.

Original languageEnglish (US)
Pages (from-to)264-277
Number of pages14
JournalMolecular imaging
Volume8
Issue number5
DOIs
StatePublished - Sep 1 2009

Fingerprint

adenoviruses
Capsid
Adenoviridae
Ovarian Neoplasms
viruses
Viruses
thymidine
cancer
Imaging techniques
Fusion reactions
fusion
Thymidine Kinase
Monitoring
Simplexvirus
Gamma Cameras
Cells
Genomic Instability
proteins
Proteins
Thymidine

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Molecular Medicine
  • Biomedical Engineering
  • Radiology Nuclear Medicine and imaging
  • Condensed Matter Physics

Cite this

Novel infectivity-enhanced oncolytic adenovirus With a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. / Kimball, Kristopher; Rivera, Angel A.; Zinn, Kurt R.; Icyuz, Mert; Saini, Vaibhav; Li, Jing; Zhu, Zeng B.; Siegal, Gene P.; Douglas, Joanne T.; Curiel, David T.; Alvarez, Ronald D.; Borovjagin, Anton V.

In: Molecular imaging, Vol. 8, No. 5, 01.09.2009, p. 264-277.

Research output: Contribution to journalArticle

Kimball, K, Rivera, AA, Zinn, KR, Icyuz, M, Saini, V, Li, J, Zhu, ZB, Siegal, GP, Douglas, JT, Curiel, DT, Alvarez, RD & Borovjagin, AV 2009, 'Novel infectivity-enhanced oncolytic adenovirus With a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer', Molecular imaging, vol. 8, no. 5, pp. 264-277. https://doi.org/10.2310/7290.2009.00025
Kimball, Kristopher ; Rivera, Angel A. ; Zinn, Kurt R. ; Icyuz, Mert ; Saini, Vaibhav ; Li, Jing ; Zhu, Zeng B. ; Siegal, Gene P. ; Douglas, Joanne T. ; Curiel, David T. ; Alvarez, Ronald D. ; Borovjagin, Anton V. / Novel infectivity-enhanced oncolytic adenovirus With a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. In: Molecular imaging. 2009 ; Vol. 8, No. 5. pp. 264-277.
@article{900019e44142446ebf8b6c35d193605b,
title = "Novel infectivity-enhanced oncolytic adenovirus With a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer",
abstract = "We sought to develop a cancer-targeted, infectivity-enhanced oncolytic adenovirus that embodies a capsid-labeling fusion for noninvasive dual-modality imaging of ovarian cancer virotherapy. A functional fusion protein composed of fl uorescent and nuclear imaging tags was genetically incorporated into the capsid of an infectivity-enhanced conditionally replicative adenovirus. Incorporation of herpes simplex virus thymidine kinase (HSV-tk) and monomeric red fl uorescent protein 1 (mRFP1) into the viral capsid and its genomic stability were verifi ed by molecular analyses. Replication and oncolysis were evaluated in ovarian cancer cells. Fusion functionality was confi rmed by in vitro gamma camera and fl uorescent microscopy imaging. Comparison of tk-mRFP virus to singlemodality controls revealed similar replication effi ciency and oncolytic potency. Molecular fusion did not abolish enzymatic activity of HSV-tk as the virus effectively phosphorylated thymidine both ex vivo and in vitro. In vitro fl uorescence imaging demonstrated a strong correlation between the intensity of fl uorescent signal and cytopathic effect in infected ovarian cancer cells, suggesting that fl uorescence can be used to monitor viral replication. We have in vitro validated a new infectivity-enhanced oncolytic adenovirus with a dual-imaging modality-labeled capsid, optimized for ovarian cancer virotherapy. The new agent could provide incremental gains toward climbing the barriers for achieving conditionally replicated adenovirus effi cacy in human trials.",
author = "Kristopher Kimball and Rivera, {Angel A.} and Zinn, {Kurt R.} and Mert Icyuz and Vaibhav Saini and Jing Li and Zhu, {Zeng B.} and Siegal, {Gene P.} and Douglas, {Joanne T.} and Curiel, {David T.} and Alvarez, {Ronald D.} and Borovjagin, {Anton V.}",
year = "2009",
month = "9",
day = "1",
doi = "10.2310/7290.2009.00025",
language = "English (US)",
volume = "8",
pages = "264--277",
journal = "Molecular Imaging",
issn = "1535-3508",
publisher = "Decker Publishing",
number = "5",

}

TY - JOUR

T1 - Novel infectivity-enhanced oncolytic adenovirus With a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer

AU - Kimball, Kristopher

AU - Rivera, Angel A.

AU - Zinn, Kurt R.

AU - Icyuz, Mert

AU - Saini, Vaibhav

AU - Li, Jing

AU - Zhu, Zeng B.

AU - Siegal, Gene P.

AU - Douglas, Joanne T.

AU - Curiel, David T.

AU - Alvarez, Ronald D.

AU - Borovjagin, Anton V.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - We sought to develop a cancer-targeted, infectivity-enhanced oncolytic adenovirus that embodies a capsid-labeling fusion for noninvasive dual-modality imaging of ovarian cancer virotherapy. A functional fusion protein composed of fl uorescent and nuclear imaging tags was genetically incorporated into the capsid of an infectivity-enhanced conditionally replicative adenovirus. Incorporation of herpes simplex virus thymidine kinase (HSV-tk) and monomeric red fl uorescent protein 1 (mRFP1) into the viral capsid and its genomic stability were verifi ed by molecular analyses. Replication and oncolysis were evaluated in ovarian cancer cells. Fusion functionality was confi rmed by in vitro gamma camera and fl uorescent microscopy imaging. Comparison of tk-mRFP virus to singlemodality controls revealed similar replication effi ciency and oncolytic potency. Molecular fusion did not abolish enzymatic activity of HSV-tk as the virus effectively phosphorylated thymidine both ex vivo and in vitro. In vitro fl uorescence imaging demonstrated a strong correlation between the intensity of fl uorescent signal and cytopathic effect in infected ovarian cancer cells, suggesting that fl uorescence can be used to monitor viral replication. We have in vitro validated a new infectivity-enhanced oncolytic adenovirus with a dual-imaging modality-labeled capsid, optimized for ovarian cancer virotherapy. The new agent could provide incremental gains toward climbing the barriers for achieving conditionally replicated adenovirus effi cacy in human trials.

AB - We sought to develop a cancer-targeted, infectivity-enhanced oncolytic adenovirus that embodies a capsid-labeling fusion for noninvasive dual-modality imaging of ovarian cancer virotherapy. A functional fusion protein composed of fl uorescent and nuclear imaging tags was genetically incorporated into the capsid of an infectivity-enhanced conditionally replicative adenovirus. Incorporation of herpes simplex virus thymidine kinase (HSV-tk) and monomeric red fl uorescent protein 1 (mRFP1) into the viral capsid and its genomic stability were verifi ed by molecular analyses. Replication and oncolysis were evaluated in ovarian cancer cells. Fusion functionality was confi rmed by in vitro gamma camera and fl uorescent microscopy imaging. Comparison of tk-mRFP virus to singlemodality controls revealed similar replication effi ciency and oncolytic potency. Molecular fusion did not abolish enzymatic activity of HSV-tk as the virus effectively phosphorylated thymidine both ex vivo and in vitro. In vitro fl uorescence imaging demonstrated a strong correlation between the intensity of fl uorescent signal and cytopathic effect in infected ovarian cancer cells, suggesting that fl uorescence can be used to monitor viral replication. We have in vitro validated a new infectivity-enhanced oncolytic adenovirus with a dual-imaging modality-labeled capsid, optimized for ovarian cancer virotherapy. The new agent could provide incremental gains toward climbing the barriers for achieving conditionally replicated adenovirus effi cacy in human trials.

UR - http://www.scopus.com/inward/record.url?scp=70349685211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349685211&partnerID=8YFLogxK

U2 - 10.2310/7290.2009.00025

DO - 10.2310/7290.2009.00025

M3 - Article

VL - 8

SP - 264

EP - 277

JO - Molecular Imaging

JF - Molecular Imaging

SN - 1535-3508

IS - 5

ER -